Hepatiq Inc

Currently used liver tests estimate the extent of fibrosis, missing the compensatory effects of liver regeneration and increased blood flow to extant functioning tissue. The fed patient is injected with a low dose standard radioisotope - Tc99m sulfur colloid. A quick 20 minute SPECT scan of the liver is acquired. The HEPATIQ software analyzes these images to provide six indices of liver disease: quantitative liver function, steatosis/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size. It also provides a physiologic stage. The HEPATIQ indices were proven to predict outcomes in the 8-year long multi-center HALT-C trial and outperformed all fibrosis tests. There are 28 publications on HEPATIQ and its clinical benefits. When fibrosis tests reach the “what now?” point, turn to HEPATIQ for more insight into the health of the liver. HEPATIQ quantifies remaining liver function thus improving prediction of disease outcomes. To use a car analogy, other tests estimate the air in the gas tank. HEPATIQ measures the gas in the gas tank. HEPATIQ is FDA cleared and the only quantitative liver function product commercially available for routine use. The scan is covered by the patient's insurance.